Treatment of isolated severe immune hemolytic anaemia associated with systemic lupus erythematosus: 26 cases

E. Gomard-Mennesson, M. Ruivard, Martial Koenig, Adrianne Woods, N. Magy‐Bertrand, N Magy, J. Ninet, H Rousset, Gilles Salles, C. Broussolle, P. Sève
In: Lupus · 2006 · vol. 15(4) , pp. 223–231 · doi:10.1191/0961203306lu2292oa · PMID:16686262 · W1978620649
article OA: closed CC0
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-08-04 ⓘ

This study evaluated 26 women with severe isolated autoimmune hemolytic anemia as the leading manifestation of SLE, finding that initial corticosteroid treatment achieved a 96% response rate with a 73% recurrence-free proportion over 180 months.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The aim of this study was to evaluate the response to treatment and the long-term outcome in a cohort of patients in whom severe autoimmune hemolytic anaemia (AHA) was the leading manifestation of systemic lupus erythematosus (SLE). Twenty-six women with severe isolated AHA were included. Corticosteroids were used as the initial treatment for all patients in our study. An initial response was obtained in all but one patient (96%). The overall recurrence rate was three per 100 person-years, with an expected recurrence-free proportion of 73% with a 180 months median follow-up. Seven patients (27%) experienced a relapse of AHA. We found a higher proportion of pleuritis in relapsing patients. Only three patients experienced multiple relapses despite splenectomy and several immunosuppressants. Steroid-sparing effect of hydroxychloroquine and azathioprine could not be assessed because most of the patients received these treatments for other reasons than AHA. Intravenous immunoglobulins induced transient response in three cases. Splenectomy was efficient to definitively control AHA in one patient but two patients quickly experienced relapses while one patient did not benefit. Five patients received immunosuppressants that induced only transient responses. Rituximab was long-term efficient in one case. In conclusion, severe AHA is a serious complication of SLE that warrants appropriate management. On the basis of our experience, the ideal treatment of isolated AHA should be oral corticosteroids in first-line treatment. Our study does not support an important role for splenectomy. Patients refractory to conventional therapy should be treated either with few toxic immunosuppressive drugs, danazol or rituximab.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (2)

References (27)

Source provenance

openalex
last seen: 2026-05-10T10:49:29.227314+00:00
unpaywall
last seen: 2026-08-19T06:23:00.919175+00:00
License: CC0 · commercial use OK